Current use of warfarin as a stroke prevention therapy in patients with nonvalvular atrial fibrillation is associated with a lower rate of residual stroke or systemic embolism compared with previous data, according to a recent study published in the Archives of Internal Medicine.
Current use of warfarin as a stroke prevention therapy in patients with nonvalvular atrial fibrillation (AF) is associated with a lower rate of residual stroke or systemic embolism compared with previous data, according to a recent study.
The meta-analysis, published in the April 23 issue of the Archives of Internal Medicine, found significant improvements in the use of warfarin for anticoagulation therapy.
AF is associated with a 5-fold increase in the risk of ischemic stroke and has been implicated as a causal factor in as many as 15% to 20% of all ischemic strokes, said Shikhar Agarwal, MD, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, and colleagues.
Although several new antithrombotic agents have been developed for stroke prevention in patients with AF, the authors predict that many physicians will continue to treat patients with warfarin because of cost considerations and a limited amount of safety data for the newer agents.
The researchers evaluated the safety and efficacy of warfarin treatment by searching the MEDLINE, EMBASE, and Cochrane databases for relevant randomized clinical trials that compared warfarin with an alternative thromboprophylaxis strategy. Their meta-analysis included 8 randomized clinical trials with 55,789 patient-years of warfarin therapy follow-up.
Dr Agarwal and colleagues found an estimated annual incidence of stroke or non-central nervous system embolism of 1.66% in patients with AF taking warfarin, 0.76% for myocardial infarction, and 3.83% for all-cause mortality. Rates of major bleeding ranged from 1.40% to 3.40% per year. Patients aged 75 years and older (2.27%), female patients (2.12%), patients with a history of stroke (2.64%), and patients reporting no previous exposure to vitamin K antagonists (1.96%) had a significantly higher annual risk of stroke.
The authors also noted a significant increase in the annual incidence of stroke in patients with increasing CHADS2 (congestive heart failure, hypertension, age, diabetes, and prior stroke) score.
“Faced with these newer choices, it is imperative that physicians precisely estimate the inherent bleeding risk accompanying warfarin treatment in eligible candidates with nonvalvular AF using current data over
historical rates obtained in the previous decade,” the authors stated.
“These results could potentially aid the decision process for warfarin therapy for individual physicians and allow health systems to evaluate the cost efficacy of adopting newer agents universally or in specific high-risk clinical subsets.”
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.